Role of lung endothelial cells during fibrotic lung remodeling.

肺内皮细胞在纤维化肺重塑中的作用。

基本信息

  • 批准号:
    10435583
  • 负责人:
  • 金额:
    $ 55.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Summary Chronic epithelial or vascular injuries followed by dysregulated repair are the trigger mechanisms in pathogenesis of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Multiple cell types are involved in lung fibrogenesis, with fibroblasts and epithelial cells given the most attention. Role of endothelial cells and microvasculature remain unclear. Dysregulated repair causes vascular remodeling, associated with increased vessel permeability, partial loss of capillaries, focal increase in pathological angiogenesis and endothelial dysfunction. Normal endothelial cells (EC) are transcriptionally re-programmed into fibrosis- associated endothelial cells (FEC), that support activated fibroblasts and promote lung inflammation. Our long- term goal is to identify key regulators of EC-to-FEC re-programming and clarify molecular mechanisms of the crosstalk between endothelial cells and other cell types during pulmonary fibrogenesis. In our preliminary data, we used endothelial cells from lungs of patients with IPF and mouse lung fibrosis models to identify FOXF1 as a key transcriptional regulator of EC-to-FEC re-programming during lung fibrogenesis. Using transgenic mouse models with endothelial-specific deletion or over-expression of Foxf1 gene, we propose to test the hypothesis that endothelial FOXF1 decreases activation of fibroblasts and prevents macrophage accumulation in fibrotic foci. We propose two specific aims: (1) identify molecular mechanisms whereby endothelial FOXF1 inhibits lung fibrogenesis, (2) establish whether restoring FOXF1 in FECs will prevent or reduce fibrotic lung remodeling after chronic lung injury. Understanding the regulation of EC-to-TEC re-programming, and the molecular mechanisms utilized by pulmonary endothelial cells to control pulmonary fibrosis, will provide new approaches for treatment of interstitial lung diseases.
总结 慢性上皮或血管损伤,随后是失调修复,是触发机制, 间质性肺疾病的发病机制,包括特发性肺纤维化(IPF)。多种细胞类型 与肺纤维化有关,其中成纤维细胞和上皮细胞最受关注。内皮细胞的作用 细胞和微脉管系统仍不清楚。修复失调导致血管重塑,与 血管通透性增加,毛细血管部分损失,病理性血管生成局灶性增加, 内皮功能障碍正常内皮细胞(EC)转录重编程为纤维化- 相关内皮细胞(FEC),支持活化的成纤维细胞并促进肺部炎症。我们长久以来- 长期目标是确定EC到FEC重编程的关键调节因子,并阐明EC到FEC重编程的分子机制。 肺纤维化发生过程中内皮细胞和其他细胞类型之间的相互作用。在我们的初步数据中, 我们使用来自IPF患者肺和小鼠肺纤维化模型的内皮细胞, 肺纤维化过程中EC到FEC重编程的关键转录调节因子。使用转基因小鼠 模型与内皮特异性缺失或过表达的Foxf 1基因,我们建议测试的假设 内皮FOXF 1减少成纤维细胞的活化并防止纤维化中巨噬细胞的积聚, 焦点我们提出了两个具体的目标:(1)确定内皮FOXF 1抑制 肺纤维化,(2)确定在FEC中恢复FOXF 1是否会预防或减少肺纤维化 慢性肺损伤后的重塑。了解EC到TEC重新编程的规则, 肺内皮细胞控制肺纤维化的分子机制,将提供新的 治疗间质性肺病的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tanya Kalin其他文献

Tanya Kalin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tanya Kalin', 18)}}的其他基金

Role of lung endothelial cells during fibrotic lung remodeling.
肺内皮细胞在纤维化肺重塑中的作用。
  • 批准号:
    10275717
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia
开发治疗肺泡毛细血管发育不良的新疗法
  • 批准号:
    10395588
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Role of lung endothelial cells during fibrotic lung remodeling.
肺内皮细胞在纤维化肺重塑中的作用。
  • 批准号:
    10646265
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia
开发治疗肺泡毛细血管发育不良的新疗法
  • 批准号:
    10579232
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia
开发治疗肺泡毛细血管发育不良的新疗法
  • 批准号:
    10218489
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Role of lung endothelial cells during fibrotic lung remodeling
肺内皮细胞在纤维化肺重塑中的作用
  • 批准号:
    10931822
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia
开发治疗肺泡毛细血管发育不良的新疗法
  • 批准号:
    10895101
  • 财政年份:
    2021
  • 资助金额:
    $ 55.08万
  • 项目类别:
Targeting Foxm1 in pulmonary fibrosis
靶向 Foxm1 治疗肺纤维化
  • 批准号:
    9151958
  • 财政年份:
    2016
  • 资助金额:
    $ 55.08万
  • 项目类别:
Targeting Foxm1 in pulmonary fibrosis
靶向 Foxm1 治疗肺纤维化
  • 批准号:
    9323554
  • 财政年份:
    2016
  • 资助金额:
    $ 55.08万
  • 项目类别:
Role of Foxm1 in Lung Cancer Microenvironment
Foxm1在肺癌微环境中的作用
  • 批准号:
    8295951
  • 财政年份:
    2010
  • 资助金额:
    $ 55.08万
  • 项目类别:

相似海外基金

Epalrestat, an aldose reductase inhibitor, alleviates bleomycin-induced skin fibrosis in mice : drug repositioning study for human systemic sclerosis
依帕司他(一种醛糖还原酶抑制剂)可减轻博来霉素诱导的小鼠皮肤纤维化:人类系统性硬化症的药物重新定位研究
  • 批准号:
    20K17346
  • 财政年份:
    2020
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapy for melanoma with the combination of bleomycin and immune checkpoint inhibitors
博来霉素和免疫检查点抑制剂联合治疗黑色素瘤
  • 批准号:
    19K08760
  • 财政年份:
    2019
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Thrombomodulin suppresses bleomycin-induced pulmonary fibrosis and develop to a new candidate for IPF treatment
血栓调节蛋白可抑制博莱霉素诱导的肺纤维化,成为 IPF 治疗的新候选药物
  • 批准号:
    19K08844
  • 财政年份:
    2019
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A role of FcgRIIB in the development of murine bleomycin-induced fibrosis model
FcgRIIB 在小鼠博莱霉素诱导的纤维化模型发展中的作用
  • 批准号:
    19K17766
  • 财政年份:
    2019
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The role of vascular endothelial growth factor receptor 1 tyrosine kinase signaling in bleomycin-induced pulmonary fibrosis
血管内皮生长因子受体1酪氨酸激酶信号在博莱霉素诱导的肺纤维化中的作用
  • 批准号:
    19K09291
  • 财政年份:
    2019
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The role of alveolar epithelial type I cells in bleomycin-induced lung injury: Characterization of fibrosis-relevant signal pathways
I 型肺泡上皮细胞在博来霉素诱导的肺损伤中的作用:纤维化相关信号通路的表征
  • 批准号:
    373703964
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Research Grants
Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced scleroderma
静脉脂肪干细胞移植对博来霉素诱导的硬皮病小鼠模型的抗炎和抗纤维化作用
  • 批准号:
    17K16216
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Changes in pulmonary endothelial cell and fibroblast properties during bleomycin-induced pulmonary fibrosis
博来霉素诱导肺纤维化过程中肺内皮细胞和成纤维细胞特性的变化
  • 批准号:
    17K09609
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Statin-polymer nanoparticles enhance the anti-inflammatory and anti-fibrotic effects of adipose-derived stem cell transplantation in a mouse model of bleomycin-induced scleroderma
他汀类聚合物纳米粒子增强博莱霉素诱导的硬皮病小鼠模型中脂肪干细胞移植的抗炎和抗纤维化作用
  • 批准号:
    17K15761
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Effect of function-blocking RHAMM peptides on adipogenesis in a bleomycin-induced scleroderma mouse model
功能阻断 RHAMM 肽对博莱霉素诱导的硬皮病小鼠模型脂肪生成的影响
  • 批准号:
    367375
  • 财政年份:
    2016
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了